• KYBORA and its Chinese translation (pronounced KAI-BO-RUI) have both been granted official trademark status by the People’s Republic of China.
  • This represents a small but important step forward to KYBORA’s continued global growth and the official opening of its offices in Shanghai later this year.
  • China is one of the most attractive biopharma markets and is forecast to a grow at a rate of 2.5-5.5% and add more than $30 billion in annual spending by 2026, driven by greater uptake and use of new original medicines.
  • KYBORA is actively working with several Chinese clients, helping them maximize the value of their assets globally (cross-border out-licensing) and in-license innovation.

About the author.

administrator

20 years of experience in international business development in the pharmaceutical industry. Head of commercial operations and business development for Bristol-Myers Squibb in 16 Latin American countries. Global management consultant. Speaks French and Spanish fluently. Completed nine transactions in global markets in the past three years.

No Comments. Leave a comment  

Leave a Reply

Your email address will not be published.

TYPE & ENTER: